Originally published In Press as doi:10.1074/jbc.M112395200 on March 7, 2002
J. Biol. Chem., Vol. 277, Issue 21, 18431-18439, May 24, 2002
Mrd1p Is Required for Processing of Pre-rRNA and for Maintenance
of Steady-state Levels of 40 S Ribosomal Subunits in Yeast*
Shao-Bo
Jin
,
Jian
Zhao
,
Petra
Björk
,
Karin
Schmekel
,
Per. O.
Ljungdahl§, and
Lars
Wieslander
¶
From the
Department of Molecular Biology and
Functional Genomics, Stockholm University, SE-106 91 Stockholm, Sweden
and the § Ludwig Institute for Cancer Research, Karolinska
Institutet, SE-171 77 Stockholm, Sweden
Received for publication, December 27, 2001, and in revised form, March 6, 2002
 |
ABSTRACT |
Ribosome biogenesis is a conserved process
in eukaryotes that requires a large number of small nucleolar RNAs and
trans-acting proteins. The Saccharomyces cerevisiae
MRD1 (multiple RNA-binding domain) gene encodes a novel protein that contains five
consensus RNA-binding domains. Mrd1p is essential for viability. Mrd1p
partially co-localizes with the nucleolar protein Nop1p. Depletion of
Mrd1p leads to a selective reduction of 18 S rRNA and 40 S ribosomal subunits. Mrd1p associates with the 35 S precursor rRNA (pre-rRNA) and
U3 small nucleolar RNAs and is necessary for the initial
processing at the A0-A2 cleavage sites in
pre-rRNA. The presence of five RNA-binding domains in Mrd1p suggests
that Mrd1p may function to correctly fold pre-rRNA, a requisite for
proper cleavage. Sequence comparisons suggest that Mrd1p homologues
exist in all eukaryotes.
 |
INTRODUCTION |
In eukaryotes, three of the four ribosomal RNAs are derived from a
single RNA polymerase I transcript, the precursor rRNA (pre-rRNA).1 Maturation of
the pre-rRNA involves a series of sequential events that occur in the
nucleolus (1, 2). These include extensive post-transcriptional
modifications of many of the nucleotides and several endo- and
exonucleolytic cleavages (3, 4) (see also Fig. 6A). The
final maturation of the 18 S rRNA in the small 40 S subunit takes place
in the cytoplasm (5), whereas the maturation of the rRNAs in the large
60 S subunit (5.8 and 25 S or 28 S rRNA from the pre-rRNA and 5 S rRNA
separately synthesized by RNA polymerase III) occurs in the nucleus
(3). The two ribosomal subunits are believed to be exported separately
from the nucleus, and export involves the Ran cycle and specific
nucleoporins (6-8).
Processing of the pre-rRNA takes place in a multicomponent complex that
is assembled co-transcriptionally (9, 10) and requires the coordinated
folding of the pre-rRNA as well as precise positioning of processing
factors (3). This process is accompanied by the assembly of ribosomal
proteins on the successive intermediates in an ordered manner to
generate the two ribosomal subunits. In Saccharomyces
cerevisiae, about 60 trans-acting proteins and 100 small nucleolar
RNAs (snoRNAs) are involved in ribosome biogenesis. The snoRNAs are
present in the form of snoRNA-protein (snoRNP) complexes in cells and
can be divided into the box (C/D) snoRNAs, the box (H/A)CA
snoRNAs, and the RNase MRP (11-13). The U3 snoRNP, one of the most
abundant and best characterized snoRNPs, is essential for processing at
the three early cleavage sites A0, A1, and
A2 that leads to the 18 S rRNA formation (9, 14, 15). In
yeast, the U3 snoRNP shares several common protein components, Nop1p, Nop5p/58p, Nop56p, and Snu 13p (16-20), with other box (C/D) snoRNPs. In addition, a set of proteins that are associated specifically with
the U3 snoRNP have been identified, including Sof1p, Mpp10p, Imp3p,
Imp4p, Lcp5p, Rcl1p, Rrp9p, and Dhr1p (21-27). Depletion of any of
these proteins or of U3 snoRNA leads to inhibition of the early
pre-rRNA cleavages at the A0-A2 cleavage sites
(in the case of Dhr1p, only the A1 and A2
sites) and reduction of the synthesis of 18 S rRNA.
Among the identified trans-acting nucleolar proteins, some are endo-
and exonucleases and RNA helicases, whereas the role of others remains
unknown (3). A shared feature of some nucleolar proteins that bind to
pre-rRNA or snoRNA is that they contain a consensus RNA-binding domain
(RBD), also called the RNA recognition motif. RBDs, which are also
present in many proteins involved in different aspects of gene
expression (28), have a typical 




-fold (29) and
mediate specific RNA binding. Two proteins essential for ribosome
biogenesis, Nop4p (30) and nucleolin (31), each contain four RBDs.
Nucleolin is involved in several steps in ribosome biogenesis (32).
Recent NMR spectroscopy studies have shown that the first two
N-terminal RBDs in nucleolin bind to an RNA stem loop present at
several sites in the pre-rRNA, and it has been suggested that nucleolin
may play a role as an RNA chaperone (33).
We have isolated and characterized a novel yeast gene MRD1
(multiple RNA-binding domain).
MRD1 encodes a protein with five consensus RNA-binding
domains that is essential for viability. Depletion of Mrd1p leads to a
decrease in the synthesis of 18 S rRNA and a decrease in the
steady-state level of 40 S ribosomal subunits. Mrd1p associates with
the 35S pre-rRNA and the U3 snoRNA. We have found that
Mrd1p is required for the initial A0-A2
cleavages during processing of the 35 S pre-rRNA. Mrd1p is the founding
member of a conserved family of proteins found in all eukaryotes, each
with multiple RNA-binding domains. The high degree of conservation
suggests that the multiple RNA-binding domains play an important
structural role in organizing specific rRNA processing events.
 |
EXPERIMENTAL PROCEDURES |
Strains--
S. cerevisiae strains are listed in
Table I. Standard yeast methods and media
are described within Guthrie and Fink (34). YPGal is similar to YPD
medium except that 2% galactose replaces glucose. Yeast cells
were transformed using the lithium acetate method (35). Transformants
were selected on solid complete synthetic dextrose media lacking
uracil, leucine, or histidine as required.
Strain HKDY8, an isogenic diploid derivative of haploid strain AA255
(36), was transformed using the NotI/SalI
fragment of pS002 (see Table II; plasmids
are described in the following section) containing the
mrd1
1::hisG-URA3-hisG allele resulting in the
Ura+ strain LWDY1. The URA3 marker in the
mrd1
1 allele of LWDY1 was converted to LEU2
resulting in strain LWDY3. This was accomplished by transforming LWDY1
to Leu+ with a HindIII fragment from plasmid
pUC4-ura3::LEU2 (obtained from Y. Kassir). LWDY1 was
propagated on media containing 5-fluoroorotic acid (5-FOA); strain
LWDY5, with the unmarked mrd1
2 allele, was isolated as a
ura
papilant. Correct insertion of deletion constructs
was confirmed by PCR and/or Southern blot analysis. Strains
LWDY3 and LWDY5 were transformed to Ura+ with pS001 and
sporulated, and tetrads were dissected. Strains LWY001 and LWY003 are
segregants obtained from these dissections, respectively. LWY001 was
transformed with plasmid pS004, and His+ transformants were
grown on media containing 5-FOA resulting in strain LWY005. Similarly,
LWY003 was transformed with pS005, and Leu+ transformants
were propagated on media containing 5-FOA to obtain strain LWY007.
The Gal+ strains were constructed as follows. Strain
W1143-1B (MAT
ura3-1 leu2-3,112 his3-11,15 met14
ade2-1 GAL2) (37) was crossed to L3906
(MATa ura3-52 trp1
1 GAL2)
(obtained from G. R. Fink). Strains PLY287 and PLY289 are haploid
segregants from this cross. Strains PLY287 and PLY289 were crossed,
creating diploid strain PLDY141. PLDY141 was transformed using the
NotI/SalI fragment of pS003 containing the
mrd1
4::HIS3 allele resulting in the
His+ strain PLDY146. PLDY146 was transformed to
Ura+ with pS001 and sporulated, and tetrads were dissected;
PLY647 is a haploid segregant. PLY647 was transformed with pS006, and Leu+ transformants were propagated on media containing
5-FOA to obtain strain LWY008.
Plasmids--
Plasmids and oligonucleotides are listed in Table
II. Pfu polymerase
(Stratagene) was used for all PCR amplifications. DNA constructs were
propagated in XL-1 Blue Escherichia coli cells (Stratagene).
The MRD1 gene (ORF YPR112c) was amplified by PCR using
oligonucleotides MRD-p5 and MRD-p3 (Table II) as primers and genomic
yeast DNA as template. The resulting fragment, containing 389 bases
upstream of the initiating ATG codon and 474 bases downstream of the
stop codon, was cloned into NotI and SalI
restricted pRS316 (38), resulting in the plasmid pS001. Precise
deletion alleles of MRD1 were created in two steps. First,
using genomic DNA as template, a 409-bp
NotI/BamHI flanked fragment containing sequences immediately 5' of the initiating ATG was amplified by PCR using primers
mrdD-p5A and mrdD-p5 (Table II). In a parallel
reaction, a 476-bp BamHI/SalI flanked fragment
containing sequences immediately 3' of the termination codon was
amplified using primers mrdD-p3A and mrdD-p3B
(Table II). After restriction with BamHI, these 5'- and
3'-PCR fragments were ligated and cloned into NotI- and
SalI-digested pBS(KS)+ (Stratagene). In step two, either a
5.1-kb BamHI/BglII fragment containing the
hisG-URA3-kanr-hisG cassette obtained
from pSE1076 (39) or a 1.8-kb BamHI fragment containing
HIS3 was ligated into the BamHI site between the
MRD1 5'- and 3'-flanking sequences, creating plasmids pS002 and pS003, respectively. An HA epitope-tagged allele of MRD1
in plasmid pS004 was created using a fusion PCR method (40) and primers
HA-MRD-A, -B, -C, and -D (Table II). The construct contains the
MRD1 promoter region (up to position
389) followed by an N-terminal HA tag and the MRD1 ORF. This construct was
inserted in NotI-SalI restricted pRS413 (41).
Plasmid pS005 contains the MRD1 ORF, amplified by PCR using
primer pairs MRD-GFP-5 and MRD-GFP-3 (Table II) using plasmid pS001 as
template, inserted into NotI- and PstI-restricted
pBFG-1/HA-GFP (42). A PstI- and NotI-flanked
fragment encoding N-terminal HA-tagged Mrd1p, amplified by PCR using
primer pair Gal-MRD-5 and Gal-MRD-3 (Table II) and pS001 as template,
was inserted into PstI-NotI-restricted B2202, creating plasmid pS006.
Immunoelectron Microscopy--
Strain LWY005 was grown to late
log phase and treated with 50 µg/ml Zymolyase 100T (Seikagaku
Corporation). Spheroplasts were fixed in 2% paraformaldehyde and 0.2%
glutaraldehyde in PBS buffer for 2 h. The fixed cells were
dehydrated in 70% ethanol for 1 h and embedded in LR White Resin
(London Resin) at 50 °C for 3 days. The thin sections were
blocked with 3% bovine serum albumin in PBS for 45 min followed by
incubation with primary antibodies (anti-HA (12CA5), diluted 1:1, and
anti-Nop1p, diluted 1:100) with 1% bovine serum albumin in PBS for
1 h. The sections were washed in PBS and incubated for 30 min with
secondary antibody (gold-conjugated mouse or rabbit IgG, 6 or 12 nm,
Jackson ImmunoResearch) diluted 1:20 in PBS containing 1% bovine
serum albumin. Sections were fixed in 4% glutaraldehyde, stained with
5% uranyl acetate, and photographed in a Zeiss electron microscope at 80kV.
In Vivo Depletion of Mrd1p--
The effect of diminished
MRD1 expression was monitored in strain LWY008 expressing
pGAL-HA-MRD1 (pS005) as described (43). Cell growth was
monitored by measuring the optical density at 600 nm over a period of
36 h. Preparations of protein and RNA were obtained from cells
harvested at the times indicated after the shift to glucose-based
medium. For each time point, an equal amount of cells was used.
Analysis of Pre-rRNA Processing--
Pulse-chase analysis of
rRNA processing was done according to Ref. 44. Briefly, strain LWY008
expressing pGAL-HA-MRD1 (pS006) was grown in SGal to an
A600 of 1. Half of the cells were resuspended in SGal, and the other half were resuspended in SD medium, and the cultures were incubated for 24 h at 30 °C. The cells were concentrated and pulse-labeled for 2 min with 250 µCi of
[methyl-3H]methionine, (PerkinElmer Life Sciences) and
chased for 1, 3, and 10 min by addition of cold methionine to a final
concentration of 5 mM. RNA was extracted using the hot
phenol method (45), and aliquots containing 40,000 cpm were
electrophoresed through 1.2% agarose-formaldehyde gels, transferred to
nylon membranes, sprayed with EN3HANCE (PerkinElmer Life
Sciences), and exposed to x-ray films.
Northern blot hybridizations were performed as described (46). For
analysis of snoRNAs, 5 µg of total RNA was electrophoresed through
6% polyacrylamide-7M urea gels. The RNA was electroblotted to
Zeta-probe membranes and probed with 32P-labeled
oligonucleotides U3, U14, U18, snR11, and snR190 (Table II).
Analysis of Polysomes and Ribosomal Subunits--
Yeast strain
LWY008 expressing pGAL-HA-MRD1 (pS006) was grown to early
log phase (A600 of 0.4) in YPGal and used to
inoculate glucose-containing YPD media. At the times indicated, cells
were harvested and lysed with glass beads, and polysomes were extracted as described (47). Extracts from 50-ml cultures were loaded onto
10-50% sucrose gradients and centrifuged in an AH-627 rotor (Sorvall)
at 4 °C for 5 h at 26,500 rpm. Fractions were monitored at 260 nm. For quantification of total ribosomal subunits, cell extracts were
prepared according to Ref. 8. Lysates from 25 ml of cultures were
loaded onto 7-25% sucrose gradients and centrifuged in an AH-650
rotor at 4 °C for 3 h at 49,500 rpm.
Analysis of nuclear extracts was performed essentially as described
(10). The extracts were centrifuged through 10-40% sucrose gradients
in an AH-650 rotor for 2 h at 50,000 rpm. The fractions were
analyzed by Northern and Western blotting. 35S pre-rRNA was
detected with a probe representing part of the 5'-ETS, and HA-Mrd1p was
detected with anti-HA antibodies.
Immunoprecipitation and Immunoblot Analysis--
Yeast strain
LWY007 expressing HA-MRD1-GFP (pS005) was grown to mid-log
phase (A600 of 0.5) in 50 ml of YPD. Cells were
washed and resuspended in 0.7 ml of lysis buffer (10 mM
Tris-HCl, pH 7.5, 5 mM MgCl2, 150 mM NaCl, 1 mM dithiothreitol, 0.2% Nonidet P-40) containing protease inhibitors (1 mM
phenylmethylsulfonyl fluoride and 2.5 µg/ml each of aprotinin,
leupeptin, pepstatin A) and 5 mM of RNase inhibitor
vanadyl ribonucleoside complex (Invitrogen). Cells were lysed by
vortexing with an equal volume of glass beads (0.4-0.5 mm, Sigma) for
5 min. Aliquots of cleared lysates (0.5 ml) were incubated with 100 µl of protein A-Sepharose and either 12CA5 or GFP antibody for 2 h at 4 °C. Mock incubations to which only protein A-Sepharose was
added were carried out in parallel. Eluted proteins were analyzed by
Western blotting using anti-Nop1 antibody and ECL reagents (Amersham Biosciences).
To detect pre-rRNA, RNA was resolved on 1.2% agarose-formaldehyde
gels. To analyze snoRNAs, RNA was electrophoresed through a 6%
denaturing polyacrylamide gel, and individual snoRNAs were detected by
hybridization with oligonucleotide probes as indicated.
 |
RESULTS |
The MRD1 Gene Is Essential for Cell Viability--
We have
recently identified a gene in the dipteran Chironomus
tentans (CTE314912) called
Ct-RBD-12 that contains six
consensus RNA-binding domains. The presence of six RBDs is unusual, and
Ct-RBD-1 appears to be involved in ribosomal synthesis and/or function.
Based on sequence similarity with Ct-RBD-1, we have identified a gene
in S. cerevisiae, ORF YPR112c on chromosome XVI, which
encodes a protein with five RBDs (Fig.
1A). We have named this
previously uncharacterized gene MRD1. Mrd1p is
comprised of 887 amino acid residues, and in addition to the five RBDs,
Mrd1p contains several putative nuclear localization sequences.
Computer searches identified Mrd1p homologues, each with a similar
domain architecture, in Saccharomyces pombe (O13620), Caenorhabditis elegans (Q9XU67), Drosophila
melanogaster (Q9VT19), and human (Q9UFN5). The S. pombe
homologue contains five RBDs, whereas the C. elegans,
D. melanogaster, C. tentans, and human proteins
all have six RBDs (Fig. 1B).

View larger version (7K):
[in this window]
[in a new window]
|
Fig. 1.
Schematic representation of the domain
structure of Mrd1p. A, Mrd1p drawn to scale with
the five RBDs shown in black. aa, amino acids.
B, the organization of RBDs in the human protein encoded by
the putative orthologous gene. The overall amino acid sequence
identity/similarity between the human protein and Mrd1p is 35.8 and
46.3%, respectively.
|
|
To characterize the function of Mrd1p, we constructed a mrd1
null allele by replacing the ORF in one of the chromosomal copies of
MRD1 with URA3 in the diploid strain HKDY8.
Subsequent tetrad analysis showed a 2:2 segregation for viability, and
no Ura+ spore-derived colonies were recovered, indicating
that the MRD1 gene is essential. Microscopic analysis
revealed that the mrd1
spores germinated, but cell
division stopped after three to four generations. To confirm the
essential nature of MRD1, the heterozygous LWDY3 strain
containing one wild-type MRD1 gene and one disrupted allele
marked with LEU2 was transformed with a URA3
centromeric plasmid (pS001) carrying the MRD1 gene under its
cognate promoter. This strain was sporulated, and tetrad analysis
showed that plasmid-borne MRD1 was able to support wild-type
growth in the cells carrying the mrd1 null allele;
Leu+ Ura+ spores were recovered at the expected frequency.
Mrd1p Co-localizes with the Nucleolar Protein Nop1p and Is Also
Present in the Nucleoplasm--
To determine the intracellular
location of Mrd1p, we constructed an allele of MRD1
(pS005) that is under the control of the phosphoglycerate kinase
promoter and that encodes a Mrd1p fusion protein with an N-terminal HA
and a C-terminal GFP. The HA-Mrd1p-GFP protein complemented
mrd1 null alleles and thus is functional. The HA-Mrd1p-GFP
fusion protein is predominantly in the nucleus and excluded from both
the vacuoles and the cytoplasm (Fig.
2A). In contrast, in cells
with the plasmid pBFG-1/HA-GFP alone, the green fluorescence was spread
throughout the cytoplasm (Fig. 2C), consistent with previous
reports (42). As compared with DAPI staining (Fig. 2B), it
was evident that HA-MRD1p-GFP was present throughout the nucleus but
that a more strongly stained crescent pattern was present within the
fluorescent nuclei. This pattern suggests that Mrd1p localizes to the
nucleolus.

View larger version (102K):
[in this window]
[in a new window]
|
Fig. 2.
Mrd1p is present in the nucleolus and the
nucleoplasm. A, yeast cells expressing Mrd1-GFP fusion
protein. Fluorescence is seen throughout the nucleus, including the
nucleolus. B, the same cells after staining with DAPI.
C, cells expressing only GFP. D and E,
immunoelectron micrographs of yeast cell nuclei. The
arrowheads show the location of HA-Mrd1p (large gold
particles) in the nucleolus and in the nucleoplasm. In panel
E, double labeling, in addition to HA-Mrd1p
(arrowheads), shows the location of Nop1p (arrows
indicating small gold particles) in the nucleolus. No,
nucleolus; Nu, nucleus. Size bars are 0.5 µm.
|
|
To more precisely determine the subcellular localization of Mrd1p, a
functional N-terminal HA-tagged Mrd1p was expressed under its cognate
promoter in the CEN vector pRS413 (pS004). The HA-Mrd1p was
localized by immunoelectron microscopy. The immunolabeling was found
throughout the nucleus including the nucleolus (Fig. 2D).
Little if any labeling was detected in the cytoplasm. Double labeling
confirmed that Mrd1p is present in the nucleolus with an overlapping
distribution of the nucleolar marker Nop1p (Fig. 2E).
Combined, our data show that Mrd1p is a nuclear protein that is
enriched in the nucleolus.
In Vivo Depletion of Mrd1p Impairs Growth and Decreases the Level
of Mature 18 S rRNA--
To determine the function of the
MRD1 gene, we analyzed the effect of depletion of Mrd1p by
using a conditional system for phenotypic analysis. The N-terminal
HA-tagged MRD1 ORF was placed under the control of a
galactose promoter (pS006). On YPGal, the pGal-HA-MRD1
allele complements the mrd1 null mutation in strain LWY008,
indicating that the HA-Mrd1p is functional.
In YPGal liquid medium, strain LWY008 showed a doubling time of ~2.2
h. Following transfer to YPD medium, in which HA-MRD1 expression is repressed, the growth rate remained similar to that of
control cells in YPGal for the first 12 h. Thereafter the doubling time began to increase significantly. After 30 h in YPD, the
generation time increased to 6 h (Fig.
3A). Concomitant with the
decrease in the growth rate, the amount of HA-Mrd1p was clearly
diminished after 6 h of incubation in the YPD medium, became very
low after 9 h, and was undetectable after 12 h (Fig.
3B). In contrast, the expression level of Nop1p remained
constant during growth in YPD medium (Fig. 3C).

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 3.
Effect of in vivo depletion
of Mrd1p on growth and ribosomal RNA. A, growth curves
of strain LWY008 grown in YPGal and after shift to YPD medium.
Generation times are plotted versus time. B,
Western blot analysis of Mrd1p in yeast cells grown for different times
in YPD medium. Each lane contains total protein from an equal amount of
cells. C, the same blot probed with anti-Nop1p antibodies.
D, equal amounts of total RNA, extracted from cells grown in
YPD medium for the indicated times, resolved by electrophoresis,
blotted to a nylon membrane, and stained with 0.03% methylene
blue.
|
|
The cessation of growth caused by reduced levels of Mrd1p was
reversible. The viability of cells grown in YPD media for 20, 30, or as
long as 40 h was examined. Around 95, 90, and 80% of the cells,
respectively, began dividing again and formed colonies when plated on
YPGal media. No colonies formed when cells were plated on YPD media.
We determined the steady-state levels of rRNAs following Mrd1p
depletion and found that the amount of 18 S rRNA was reduced dramatically, whereas the abundance of the 25 S rRNAs was not affected (Fig. 3D). It is unlikely that the decreased
steady-state level of 18 S rRNA was due to the effect of cell death
because (a) at least more than 90% of cells grown in YPD
medium were still viable at the relevant time points based on the cell
viability test and (b) the 5.8 S rRNA levels were not
affected (data not shown). Further, the levels of Nop1p did not change
during the experiment (Fig. 3C). These observations indicate
that Mrd1p could have a direct role in 18 S rRNA metabolism.
Mrd1p Depletion Leads to a Deficiency of 40 S Ribosomal
Subunits--
Since Mrd1p is located in the nucleolus and its
depletion leads to a decrease in cell growth and a reduction in the
level of 18 S rRNA, we explored the possible function of Mrd1p in
ribosome biogenesis. In Fig. 4, it is
demonstrated that depletion of Mrd1p leads to drastic changes in the
polysome profile. As compared with the profile in cells expressing
Mrd1p (Fig. 4A), there is a gradual decrease in
polyribosomes and 80 S monosomes with time (Fig. 4, B and
C). Simultaneously, there is a decrease in the amount of 40 S ribosomal subunits and a relative increase in 60 S ribosomal
subunits. The 40 S ribosomal subunit deficit was further examined by
analysis of the total amount of ribosomal subunits (Fig.
4D). The A260 60 S:40 S ratio for the LWY008
strain increased drastically after 24 h in YPD medium (Fig.
4E). Taken together, these data show that depletion of Mrd1p
leads to a decrease of 40 S ribosomal subunits.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 4.
Depletion of Mrd1p results in deficits of 40 S ribosomal subunits. A-C, 10-50% sucrose gradient
profiles from the LWY008 strain, displaying polysomes, monoribosomes,
and ribosomal subunits. Cells were grown in YPGal medium (A)
or YPD medium (B and C) for the indicated times.
D and E, ribosomal subunits in extracts of LWY008
cells, resolved in 7-25% sucrose gradients. Cells were grown in YPGal
medium (D) or YPD medium (E) for 30 h. Peaks
representing free 40 or 60 S ribosomal subunits or 80 S monoribosomes
are labeled.
|
|
18 S rRNA Synthesis Is Impaired upon Mrdp1 Depletion--
To
determine whether the reduction in the levels of 18 S rRNA and 40 S
ribosomal subunits following the depletion of Mrd1p was due to defects
in pre-rRNA processing, the pre-rRNA processing pathway was directly
followed by using pulse-chase labeling analysis (Fig.
5; see also Fig. 6A for a
schematic view of the pre-rRNA processing). In the cells expressing the
MRD1 gene, the 35 S pre-rRNA was rapidly processed to yield
27 and 20 S pre-rRNA intermediates as detected after 1 min of chase
(Fig. 5, SGal). After 3 min of chase, the 35 S precursor
disappeared, and most of the 27 and 20 S intermediates were processed
to 25 S rRNA and 18 S rRNA. The processing appeared to be completed
within 10 min since all of the labeling was chased into mature 25 and
18 S rRNAs. However, in the Mrd1p-depleted cells, processing is slowed
down with an increased amount of the 35 S precursor (Fig. 5,
SD). After up to 3 min of chase, a significant amount of 35 S precursor was still present. Processing into 27 S pre-rRNA
intermediates and 25 S rRNA was not affected. In contrast, processing
into the 20 S pre-rRNA intermediate and 18 S rRNA was severely
impaired. Thus, accumulation of 35 S pre-rRNA followed by reduced
formation of the 20 S pre-rRNA intermediate leads to a net decrease and
delay in 18 S rRNA production in the Mrd1p-depleted cells. This is
consistent with our observations from the ribosomal gradient analysis
that the amount of 40 S subunits decreased.

View larger version (83K):
[in this window]
[in a new window]
|
Fig. 5.
Mrd1p depletion results in reduced synthesis
of 18 S rRNA. LWY008 cells were labeled with
[methyl-3H]methionine for 2 min followed by chase with
cold methionine for 1, 3, and 10 min. RNA was separated on denaturing
agarose gels, transferred to a nylon filter, and visualized by
fluorography. The positions of processing intermediates and products
are indicated.
|
|
Mrd1p Is Required for the Initial Processing of Pre-rRNA at the
A0-A2 Sites--
To assess the role of Mrd1p
in pre-rRNA processing in more detail, we analyzed the steady-state
levels of the pre-rRNA processing intermediates upon depletion of
Mrd1p. The yeast pre-rRNA processing pathway and the locations of the
oligonucleotide probes used to detect 5'-ETS, -ITS1, and -ITS2 are
shown in Fig. 6A. Equal
amounts of total RNA prepared from the LWY008 strain (harvested after growth for 0, 16, 24, and 30 h in YPD medium) were subjected to Northern blot analysis (Fig. 6B). When probe 1, which
hybridizes to a sequence upstream of the A0 site, was used,
little 35 S was detected in the control RNA extract (Fig.
6B, probe 1, lane 1; see also
probes 2-4, lane 1), consistent with the known
rapid processing of this precursor in wild-type cells. In the
Mrd1p-depleted cells, the amount of the 35 S pre-rRNA increased. This
accumulation was also detected with all probes that could detect the 35 S pre-rRNA precursor (Fig. 6B, probes 2-4,
lanes 2-4), showing the inhibition of cleavage at site
A0. Meanwhile, we also detected an increase of the 23 S
aberrant pre-rRNA intermediate (Fig. 6B, probe 1, lanes 2-4), which is the product of cleavage of the 35 S
pre-rRNA at site A3 in the absence of prior cleavage at
sites A0-A2 (48). The 23 S aberrant pre-rRNA
intermediate could also be seen when hybridizing with probes 2 and 3 at
the 5'-side of A2 and A3 cleavage sites,
respectively (Fig. 6B, probes 2 and 3,
lanes 2-4). We also detected a decrease in the amount of 20 S (Fig. 6B, probe 2), which is consistent with
the inhibition of cleavage at A2. Hybridization with probe
4, specific for the precursor containing 5.8 and 25 S rRNAs, showed
that the cleavages at the A3 and downstream sites were not
affected upon Mrd1p depletion (Fig. 6B, probe
4).

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 6.
Mrd1p is required for pre-rRNA processing at
A0, A1, and A2. A,
schematic representation of the pre-rRNA and the major processing
intermediates detected by the four oligonucleotide probes. Cleavage
sites A0-E are indicated as well as the positions of the
four probes (1-4). B, Northern blots hybridized with probes
1-4. The positions of the 35 S pre-rRNA and the different processing
intermediates are indicated. Probe number 4 will detect the four
different 27 S intermediates shown in panel A, collectively
marked as 27S.
|
|
Based on these results, we conclude that depletion of Mrd1p leads to
increased levels of 35 S pre-rRNA and the 23 S aberrant pre-rRNA
intermediate. These effects are concordant with impaired pre-rRNA
processing at sites A0, A1, and A2.
Consistently, we observed decreased levels of the 20 S pre-rRNA
intermediate and 18 S rRNA. Although our results are indicative of
severely impaired processing, some 20 S pre-rRNA intermediate
and 18 S rRNA were still produced, and 35 S and the aberrant 23 S
pre-rRNA intermediate did not accumulate to very high levels.
Mrd1p Is Associated with the 35 S Pre-rRNA and U3
snoRNA--
Our results show that Mrd1p is involved in the initial
cleavages of the 35 S pre-rRNA. If so, Mrd1p is most likely physically associated with the pre-rRNA precursor. In Fig.
7A, it is shown that 35 S
pre-rRNA and Mrd1p are both present in 80-90 S particles in the
nucleus. As a further test, we immunoprecipitated cell extracts from
cells expressing the HA-Mrd1p-GFP fusion protein with anti-GFP or
anti-HA antibodies. In Fig. 7B, it is shown that 35 S
pre-rRNA could be detected in the immunoprecipitated Mrd1p complex.
These results suggest that Mrd1p interacts with the 35 S pre-rRNA and
are consistent with the fact that Mrd1p is necessary for efficient
cleavage at the A0-A2 cleavage sites.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 7.
Mrd1p is associated with 35 S pre-rRNA,
Nop1p, and U3 snoRNA. A, a nuclear extract from LWY008
cells, expressing HA-Mrd1p, was centrifuged through a 10-40% sucrose
gradient. 35 S pre-rRNA and Mrd1p were both located in 80-90 S
particles by Northern and Western blotting, respectively. In
B-D, whole-cell extracts from LWY007 cells, expressing
HA-Mrd1p-GFP, immunoprecipitated with or without anti-GFP antibodies.
In panel B, 35 S pre-rRNA was detected by Northern blot
analysis using oligonucleotide probe 2 (see the legend for Fig. 6)
after immunoprecipitation with the anti-GFP antibody (lane
3) but not when the anti-GFP antibody was left out (lane
2). Total RNA is shown as a size control (lane 1). In
panel C, the immunoprecipitated RNA was electroblotted and
probed with oligonucleotide probes specific for the indicated snoRNAs.
U3 snoRNA was specifically precipitated with the anti-GFP antibody
(lane 2) but not in controls without anti-GFP antibodies
(lane 3). The positions of the different snoRNAs are shown
in total RNA (lane 1). In panel D,
immunoprecipitated proteins were analyzed by Western blotting. Nop1p
was detected when anti-GFP antibodies were used (lane 3) but
not when anti-GFP antibodies were left out (lane 2). Nop1p
in a total cell extract is shown in lane 1.
|
|
Impaired pre-rRNA processing at the A0-A2
processing sites is also observed after depletion of the snoRNAs U3,
U14, and snR10 and several nucleolar proteins. We therefore used
co-immunoprecipitation to assay whether Mrd1p is associated with some
of these factors. Extracts from cells expressing the HA-Mrd1-GFP fusion
protein were immunoprecipitated with anti-GFP antibodies. The
immunoprecipitated RNA was separated on 6% polyacrylamide gels and
probed with oligonucleotides specific to several box (C/D) (U3, U14,
U18, snR190) snoRNAs and the box (H/A)CA (snR11) snoRNAs. Only U3
snoRNA specifically co-immunoprecipitated with the Mrd1 fusion protein
(Fig. 7C). The same result was obtained when anti-HA
antibody was used for immunoprecipitation (data not shown). We also
showed that the U3 snoRNP protein Nop1 could be co-immunoprecipitated
with Mrd1p (Fig. 7D).
Finally, we tested the stability of the U3, U14, U18, snR11, and snR190
snoRNAs following Mrd1p depletion (Fig.
8). The hybridization signals from
Mrd1p-depleted cells were not different from those seen from cells
grown in galactose medium. This suggests that the effect of Mrd1p
depletion is not due to a decrease in the amount of snoRNAs.

View larger version (60K):
[in this window]
[in a new window]
|
Fig. 8.
Levels of U3 snoRNA and several other snoRNAs
are not affected following depletion of Mrd1p. Total RNA was
extracted from LWY008 cells grown in YPD for the indicated times and
separated on 6% polyacrylamide gels. After electroblotting to a nylon
filter, the RNA was hybridized with oligonucleotide probes specific for
the indicated snoRNAs.
|
|
 |
DISCUSSION |
Mrd1p Together with Several Other Components Contribute to the
Initial Processing of Pre-rRNA--
The MRD1 gene is
essential for cell growth. We demonstrated that Mrd1p is required for
maintaining steady-state levels of the 40 S ribosomal subunit. Analysis
of the effect of Mrd1p depletion showed that the 35 S pre-rRNA and the
aberrant 23 S pre-rRNA intermediate increased and that the levels of
the 20 S pre-rRNA intermediate and 18 S rRNAs were reduced. This is
characteristic of a specific inhibition of processing at the
A0-A2 sites. The aberrant 23 S pre-rRNA
intermediate cannot be further processed to 18 S rRNA and is known to
be rapidly degraded by the exosome (49). The inhibition of cleavage at
the A0-A2 sites was significant, but some 18 S
rRNA could still be made. The fact that we did not detect any changes
in the steady-state levels of the U3, U14, U18, snR11, and snR190
snoRNAs showed that the effect of Mrd1p depletion is not due to a
defect in the synthesis or stability of these snoRNAs. Rather,
our results showing that Mrd1p is associated with the 35 S pre-rRNA in
the 80-90 S pre-rRNP particle suggest a more direct role for Mrd1p in
pre-rRNA processing.
Mrd1p is co-immunoprecipitated with U3 snoRNA (and the U3
snoRNP-associated Nop1p). It is established that U3 snoRNA base-pairs to the 35 S pre-rRNA at the 5'-ETS and also at the 5'-stem loop within
the 18 S rRNA. These interactions are needed for the early A0-A2 cleavages and A1 and
A2 cleavages, respectively (11). Our immunoprecipitation
results therefore are in agreement with the interpretation that Mrd1p
and the U3 snoRNA are both bound to the 35 S pre-rRNA
precursor. Although it is likely that these interactions
occur in a region of the 35 S rRNA precursor containing the 5'-ETS and
18 S rRNA, our data do not rule out other alternatives.
Several components have been shown previously to be necessary for
processing at the A0-A2 sites. These include
the U3, U14, snR30, and snR10 snoRNAs and the snoRNP proteins, Nop1p,
Sof1p, and Gar1p (16, 21, 50-54), the putative helicases Fal1p (44), Rrp3p (55), and Rok1p (56), the dimethylase Dim1p (57), and the
nucleolin-like Nsr1p (58). Mutations in different components have shown
that processing at the three sites is interconnected but not
necessarily coupled (57, 59). Many different components are involved in
all three processing events, indicating that the A0,
A1, and A2 cleavages take place in a
multi-snoRNP complex (60). Processing at the
A0-A2 sites is also coupled to cleavage at the
A3 site, suggesting that contacts between processing
factors can bridge longer distances in a large pre-rRNA-protein complex (61, 62). The structure of Mrd1p and its association with the 35 S pre-rRNA and U3 snoRNA, combined with its involvement in the
processing of three separate cleavage sites, are consistent with a
model in which Mrd1p binds to the pre-rRNA and/or snoRNAs in a complex
that is required for the processing reactions.
Mrd1p May Play a Role in Organizing the Pre-rRNA in the
Multicomponent RNA-protein Processing Complex--
A notable feature
of Mrd1p is the presence of five RNA-binding domains. One or up to four
RBDs are present in a large number of different proteins (29). The
structure of several individual RBDs (63, 64) as well as two
consecutive RBDs, complexed with RNA, have been determined (33, 65,
66). Each RBD has a 




-fold. Individual RBDs interact
with specific sequences of up to 12 nucleotides, present in stem loops
or in linear RNA. Two consecutive RBDs in nucleolin (33) bind on
opposite sides of an RNA loop, thus stabilizing the stem loop,
whereas in sex-lethal (66) and poly(A)-binding protein (65), two
consecutive RBDs bind and stretch the RNA.
It is most likely that the five RBDs in Mrd1p are all folded into the
compact RBD 




-structure and that they contribute to
binding to specific sequences in the 35 S pre-rRNA or in snoRNAs. In
Mrd1p, the distances between the five RBDs are unusually long, 285, 127, 76, and 42 amino acid residues (Fig. 1A). These regions could facilitate specific interactions with other proteins within the
pre-rRNA-protein complex.
Why is Mrd1p necessary for the initial pre-rRNA processing steps?
Cleavages at the A0-A2 sites require many
different components in the pre-rRNP processing complex. The
conformation of the pre-rRNA and the snoRNAs may be important to
accomplish a cleavage-competent substrate. It has recently been
proposed that nucleolin via its RBDs binds a GC-rich sequence present
several times in pre-rRNA, to induce or stabilize stem-loop structures,
and serves as an RNA chaperone (33). It has also been proposed that a
cleavage-competent pre-rRNP structure requires that several RNA-binding
proteins interact with the different spacer sequences in the 35 S
pre-rRNA (67). Proteins have been identified that assist in the
formation of specific rRNA tertiary structures; thus, these proteins
inhibit other possible alternative base pairings that can kinetically trap rRNA molecules in inactive conformations (68). Based on the
current understanding of Mrd1p, we suggest that Mrd1p binding to
pre-rRNA facilitates the proper folding of rRNA for cleavage at the
A0-A2 processing sites. Mrd1p has a similar
sequence organization to proteins in several eukaryotic organisms (see
"Results"), and it has a similar nuclear localization to
proteins in Diptera and human.2 This suggests that Mrd1p is
evolutionarily conserved in eukaryotes and that the functional
properties of Mrd1p revealed here are of general importance.
 |
ACKNOWLEDGEMENTS |
We gratefully acknowledge A. Mutvei for the
gift of the anti-Nop1p antibody. We thank G. R. Fink for yeast
strain L3906, Y. Kassir for plasmid pUC4-ura3::LEU2, D. Miller for plasmid B2202, and R. Yelin for plasmid BFG-1GFP.
 |
FOOTNOTES |
*
This work was supported by The Swedish Research Council,
Natural and Engineering Sciences, Magnus Bergvalls Stiftelse (to L. W.) and Carl Tryggers Stiftelse (to L. W.) and the Ludwig
Institute for Cancer Research (to P. O. L.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed. Tel: 46-8-161720;
Fax: 46-8-166488; E-mail: Lars.Wieslander@molbio.su.se.
Published, JBC Papers in Press, March 7, 2002, DOI 10.1074/jbc.M112395200
2
P. Björk, G. Banrén, S.-B. Jin,
Y.-G. Tong, T. R. Bürglin, U. Hellman, and L. Wieslander, in preparation.
 |
ABBREVIATIONS |
The abbreviations used are:
pre-rRNA, precursor rRNA;
snoRNA, small nucleolar RNAs;
snoRNP, snoRNA-protein;
pre-rRNP, precursor ribosomal ribonucleoprotein;
MRD, multiple
RNA-binding domain;
RBD, RNA-binding domain;
5-FOA, 5-fluoroorotic
acid;
ORF, open reading frame;
HA, hemagglutinin;
PBS, phosphate-buffered saline;
ETS, external transcribed spacer;
GFP, green
fluorescent protein.
 |
REFERENCES |
| 1.
|
Eichler, D. C.,
and Craig, N.
(1994)
Prog. Nucleic Acid Res. Mol. Biol.
49,
197-239[Medline]
[Order article via Infotrieve]
|
| 2.
|
Leary, D. J.,
and Huang, S.
(2001)
FEBS Lett.
509,
145-150[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Kressler, D.,
Linder, P.,
and de La Cruz, J.
(1999)
Mol. Cell. Biol.
19,
7897-7912[Free Full Text]
|
| 4.
|
Olson, M. O.,
Dundr, M.,
and Szebeni, A.
(2000)
Trends Cell Biol.
10,
189-196[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Udem, S. A.,
and Warner, J. R.
(1973)
J. Biol. Chem.
248,
1412-1416[Abstract/Free Full Text]
|
| 6.
|
Hurt, E.,
Hannus, S.,
Schmelzl, B.,
Lau, D.,
Tollervey, D.,
and Simos, G.
(1999)
J. Cell Biol.
144,
389-401[Abstract/Free Full Text]
|
| 7.
|
Moy, T. I.,
and Silver, P. A.
(1999)
Genes Dev.
13,
2118-2133[Abstract/Free Full Text]
|
| 8.
|
Stage-Zimmermann, T.,
Schmidt, U.,
and Silver, P. A.
(2000)
Mol. Biol. Cell
11,
3777-3789[Abstract/Free Full Text]
|
| 9.
|
Mougey, E. B.,
Pape, L. K.,
and Sollner-Webb, B.
(1993)
Mol. Cell. Biol.
13,
5990-5998[Abstract/Free Full Text]
|
| 10.
|
Trapman, J.,
Retel, J.,
and Planta, R. J.
(1975)
Exp. Cell Res.
90,
95-104[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Tollervey, D.,
and Kiss, T.
(1997)
Curr. Opin Cell Biol.
9,
337-342[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Weinstein, L. B.,
and Steitz, J. A.
(1999)
Curr. Opin. Cell Biol.
11,
378-384[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Filipowicz, W.,
Pelczar, P.,
Pogacic, V.,
and Dragon, F.
(1999)
Acta Biochim. Pol.
46,
377-389[Medline]
[Order article via Infotrieve]
|
| 14.
|
Enright, C. A.,
Maxwell, E. S.,
Eliceiri, G. L.,
and Sollner-Webb, B.
(1996)
RNA (N. Y.)
2,
1094-1099
|
| 15.
|
Kass, S.,
Tyc, K.,
Steitz, J. A.,
and Sollner-Webb, B.
(1990)
Cell
60,
897-908[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Tollervey, D.,
Lehtonen, H.,
Carmo-Fonseca, M.,
and Hurt, E. C.
(1991)
EMBO J.
10,
573-583[Medline]
[Order article via Infotrieve]
|
| 17.
|
Wu, P.,
Brockenbrough, J. S.,
Metcalfe, A. C.,
Chen, S.,
and Aris, J. P.
(1998)
J. Biol. Chem.
273,
16453-16463[Abstract/Free Full Text]
|
| 18.
|
Lafontaine, D. L.,
and Tollervey, D.
(1999)
RNA (N. Y.)
5,
455-467
|
| 19.
|
Gautier, T.,
Berges, T.,
Tollervey, D.,
and Hurt, E.
(1997)
Mol. Cell. Biol.
17,
7088-7098[Abstract]
|
| 20.
|
Watkins, N. J.,
Segault, V.,
Charpentier, B.,
Nottrott, S.,
Fabrizio, P.,
Bachi, A.,
Wilm, M.,
Rosbash, M.,
Branlant, C.,
and Luhrmann, R.
(2000)
Cell
103,
457-466[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Jansen, R.,
Tollervey, D.,
and Hurt, E. C.
(1993)
EMBO J.
12,
2549-2558[Medline]
[Order article via Infotrieve]
|
| 22.
|
Dunbar, D. A.,
Wormsley, S.,
Agentis, T. M.,
and Baserga, S. J.
(1997)
Mol. Cell. Biol.
17,
5803-5812[Abstract]
|
| 23.
|
Lee, S. J.,
and Baserga, S. J.
(1999)
Mol. Cell. Biol.
19,
5441-5452[Abstract/Free Full Text]
|
| 24.
|
Wiederkehr, T.,
Pretot, R. F.,
and Minvielle-Sebastia, L.
(1998)
RNA (N. Y.)
4,
1357-1372
|
| 25.
|
Billy, E.,
Wegierski, T.,
Nasr, F.,
and Filipowicz, W.
(2000)
EMBO J.
19,
2115-2126[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Venema, J.,
Vos, H. R.,
Faber, A. W.,
van Venrooij, W. J.,
and Raue, H. A.
(2000)
RNA (N. Y.)
6,
1660-1671
|
| 27.
|
Colley, A.,
Beggs, J. D.,
Tollervey, D.,
and Lafontaine, D. L.
(2000)
Mol. Cell. Biol.
20,
7238-7246[Abstract/Free Full Text]
|
| 28.
|
Burd, C. G.,
and Dreyfuss, G.
(1994)
Science
265,
615-621[Abstract/Free Full Text]
|
| 29.
|
Varani, G.,
and Nagai, K.
(1998)
Annu. Rev. Biophys. Biomol. Struct.
27,
407-445[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Sun, C.,
and Woolford, J. L., Jr.
(1997)
J. Biol. Chem.
272,
25345-25352[Abstract/Free Full Text]
|
| 31.
|
Orrick, L. R.,
Olson, M. O.,
and Busch, H.
(1973)
Proc. Natl. Acad. Sci. U. S. A.
70,
1316-1320[Abstract/Free Full Text]
|
| 32.
|
Ginisty, H.,
Sicard, H.,
Roger, B.,
and Bouvet, P.
(1999)
J. Cell Sci.
112,
761-772[Abstract]
|
| 33.
|
Allain, F. H.,
Bouvet, P.,
Dieckmann, T.,
and Feigon, J.
(2000)
EMBO J.
19,
6870-6881[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Guthrie, C., and Fink, G. R.
(eds)
(1991)
Methods in Enzymology, Vol. 194, Guide to Yeast Genetics and Molecular Biology
, Academic Press Inc., San Diego, CA
|
| 35.
|
Gietz, D., St,
Jean, A.,
Woods, R. A.,
and Schiestl, R. H.
(1992)
Nucleic Acids Res.
20,
1425[Free Full Text]
|
| 36.
|
Antebi, A.,
and Fink, G. R.
(1992)
Mol. Biol. Cell
3,
633-654[Abstract]
|
| 37.
|
Thomas, B. J.,
and Rothstein, R.
(1989)
Cell
56,
619-630[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Sikorski, R. S.,
and Hieter, P.
(1989)
Genetics
122,
19-27[Abstract/Free Full Text]
|
| 39.
|
Allen, J. B.,
and Elledge, S. J.
(1994)
Yeast
10,
1267-1272[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Ho, S. N.,
Hunt, H. D.,
Horton, R. M.,
Pullen, J. K.,
and Pease, L. R.
(1989)
Gene (Amst.)
77,
51-59[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Brachmann, C. B.,
Davies, A.,
Cost, G. J.,
Caputo, E., Li, J.,
Hieter, P.,
and Boeke, J. D.
(1998)
Yeast
14,
115-132[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Yelin, R.,
and Schuldiner, S.
(2001)
Biochim. Biophys. Acta
1510,
426-441[Medline]
[Order article via Infotrieve]
|
| 43.
|
Hong, B.,
Brockenbrough, J. S., Wu, P.,
and Aris, J. P.
(1997)
Mol. Cell. Biol.
17,
378-388[Abstract]
|
| 44.
|
Kressler, D.,
de la Cruz, J.,
Rojo, M.,
and Linder, P.
(1997)
Mol. Cell. Biol.
17,
7283-7294[Abstract]
|
| 45.
|
Ausubel, F. M.,
Brent, R.,
Kingston, R. E.,
Moore, D. D.,
Seidman, J. G.,
Smith, J. S.,
and Struhl, K.
(2000)
Current Protocols in Molecular Biology Online
, John Wiley & Sons, New York
|
| 46.
|
Sambrook, J.,
and Russel, D. W.
(2001)
Molecular Cloning: A Laboratory Manual
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 47.
|
Pintard, L.,
Kressler, D.,
and Lapeyre, B.
(2000)
Mol. Cell. Biol.
20,
1370-1381[Abstract/Free Full Text]
|
| 48.
|
Tollervey, D.
(1996)
Exp. Cell Res.
229,
226-232[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Venema, J.,
and Tollervey, D.
(1999)
Annu. Rev. Genet.
33,
261-311[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Li, H. D.,
Zagorski, J.,
and Fournier, M. J.
(1990)
Mol. Cell. Biol.
10,
1145-1152[Abstract/Free Full Text]
|
| 51.
|
Hughes, J. M.,
and Ares, M., Jr.
(1991)
EMBO J.
10,
4231-4239[Medline]
[Order article via Infotrieve]
|
| 52.
|
Girard, J. P.,
Lehtonen, H.,
Caizergues-Ferrer, M.,
Amalric, F.,
Tollervey, D.,
and Lapeyre, B.
(1992)
EMBO J.
11,
673-682[Medline]
[Order article via Infotrieve]
|
| 53.
|
Morrissey, J. P.,
and Tollervey, D.
(1993)
Mol. Cell. Biol.
13,
2469-2477[Abstract/Free Full Text]
|
| 54.
|
Beltrame, M.,
Henry, Y.,
and Tollervey, D.
(1994)
Nucleic Acids Res.
22,
4057-4065[Abstract/Free Full Text]
|
| 55.
|
O'Day, C. L.,
Chavanikamannil, F.,
and Abelson, J.
(1996)
Nucleic Acids Res.
24,
3201-3207[Abstract/Free Full Text]
|
| 56.
|
Venema, J.,
Bousquet-Antonelli, C.,
Gelugne, J. P.,
Caizergues-Ferrer, M.,
and Tollervey, D.
(1997)
Mol. Cell. Biol.
17,
3398-3407[Abstract]
|
| 57.
|
Lafontaine, D.,
Vandenhaute, J.,
and Tollervey, D.
(1995)
Genes Dev.
9,
2470-2481[Abstract/Free Full Text]
|
| 58.
|
Lee, W. C.,
Xue, Z. X.,
and Melese, T.
(1991)
J. Cell Biol.
113,
1-12[Abstract/Free Full Text]
|
| 59.
|
Venema, J.,
Henry, Y.,
and Tollervey, D.
(1995)
EMBO J.
14,
4883-4892[Medline]
[Order article via Infotrieve]
|
| 60.
|
Morrissey, J. P.,
and Tollervey, D.
(1995)
Trends Biochem. Sci.
20,
78-82[CrossRef][Medline]
[Order article via Infotrieve]
|
| 61.
|
Allmang, C.,
Henry, Y.,
Morrissey, J. P.,
Wood, H.,
Petfalski, E.,
and Tollervey, D.
(1996)
RNA (N. Y.)
2,
63-73
|
| 62.
|
Venema, J.,
and Tollervey, D.
(1996)
EMBO J.
15,
5701-5714[Medline]
[Order article via Infotrieve]
|
| 63.
|
Oubridge, C.,
Ito, N.,
Evans, P. R.,
Teo, C. H.,
and Nagai, K.
(1994)
Nature
372,
432-438[CrossRef][Medline]
[Order article via Infotrieve]
|
| 64.
|
Price, S. R.,
Evans, P. R.,
and Nagai, K.
(1998)
Nature
394,
645-650[CrossRef][Medline]
[Order article via Infotrieve]
|
| 65.
|
Deo, R. C.,
Bonanno, J. B.,
Sonenberg, N.,
and Burley, S. K.
(1999)
Cell
98,
835-845[CrossRef][Medline]
[Order article via Infotrieve]
|
| 66.
|
Handa, N.,
Nureki, O.,
Kurimoto, K.,
Kim, I.,
Sakamoto, H.,
Shimura, Y.,
Muto, Y.,
and Yokoyama, S.
(1999)
Nature
398,
579-585[CrossRef][Medline]
[Order article via Infotrieve]
|
| 67.
|
Lalev, A. I.,
Abeyrathne, P. D.,
and Nazar, R. N.
(2000)
J. Mol. Biol.
302,
65-77[CrossRef][Medline]
[Order article via Infotrieve]
|
| 68.
|
Herschlag, D.
(1995)
J. Biol. Chem.
270,
20871-20874[Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati